Core Insights - The study results presented at the ESMO Asia Congress 2025 indicate that the combination therapy of osemitamab with nivolumab and CAPOX shows promising clinical benefits for patients with advanced gastric or gastroesophageal junction adenocarcinoma [1][2] Group 1: Clinical Efficacy - The updated efficacy analysis from the TranStar102 trial shows a median progression-free survival (mPFS) of 16.6 months and an objective response rate (ORR) of 68% among 26 patients with CLDN18.2 expression ≥40% and known PD-L1 CPS [1] - The median duration of response (mDoR) is reported to be 18 months, indicating sustained efficacy of the treatment [1] - Higher CLDN18.2 expression correlates with better PFS outcomes regardless of PD-L1 expression levels, suggesting consistent therapeutic benefits across different patient subgroups [1] Group 2: Safety and Tolerability - The safety profile of the combination therapy remains consistent with previously reported data, indicating good tolerability and safety [1][2] - The treatment is expected to provide significant clinical benefits to patients who urgently need more effective treatment options for advanced gastric or gastroesophageal junction adenocarcinoma [2]

Core Insights - The company announced positive results from the TranStar102 clinical trial, which evaluated osemitamab in combination with nivolumab and CAPOX for the treatment of gastric or gastroesophageal junction adenocarcinoma [1][2] - The updated efficacy analysis showed a median progression-free survival (mPFS) of 16.6 months and an objective response rate (ORR) of 68% among patients with high CLDN18.2 expression [1] - The results indicate that the treatment benefits of osemitamab are consistent across different PD-L1 expression subgroups, suggesting its potential effectiveness for a broader patient population [2] Efficacy Analysis - The study involved 26 patients with CLDN18.2 expression ≥40% and PD-L1 CPS known, with a median follow-up of 25.8 months [1] - The median duration of response (mDoR) was reported at 18 months, highlighting the durability of the treatment response [1] - The analysis confirmed that higher CLDN18.2 expression correlates with better PFS outcomes, regardless of PD-L1 expression levels [1] Safety Profile - The safety characteristics of the treatment were consistent with previously reported data from the ASCO 2025 conference [2] - The combination therapy demonstrated good safety and tolerability, reinforcing its potential as a first-line treatment option for advanced gastric or gastroesophageal junction adenocarcinoma [2] - The clinical benefits observed in the study are expected to provide significant improvements for patients in need of more effective treatment options [2]